American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure

Anversa L, 2018, Human leishmaniasis in Brazil: a general review, Rev Assoc Med Bras (1992), 64, 281, 10.1590/1806-9282.64.03.281 Almeida OL, 2011, Advances in the treatment of cutaneous leishmaniasis in the New World in the last ten years: a systematic literature review, An Bras Dermatol, 86, 497 Reveiz L, 2013, Intervention for American cutaneous and mucocutaneous leishmaniasis: A systematic review update, PLoS One, 8, 10.1371/journal.pone.0061843 Oliveira LF, 2011, Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World, Acta Trop, 118, 87, 10.1016/j.actatropica.2011.02.007 Clementi A, 2011, Renal involvement in leishmaniasis: a review of the literature, NDT Plus, 4, 147 Lyra MR, 2016, Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis, Rev Inst Med Trop Sao Paulo, 58, 68 El Jeri HK, 2017, Visceral leishmaniasis in adults with nephropathy, Saudi J Kidney Dis Transpl, 28, 95, 10.4103/1319-2442.198159 Fontenele e Silva JS, 2013, Treatment of American tegumentary leishmaniasis in special population: a summary of evidence, Rev Soc Bras Med Trop, 46, 669, 10.1590/0037-8682-0104-2013 Bellmann R, 2017, Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients, Infection, 45, 737, 10.1007/s15010-017-1042-z